Skip to content
OpenCapital
Get started

Omnicell OMCL Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

Guardant Health logo
Guardant HealthGH
$1.5B+34.7%

Other financials

Income statement

See full
Revenue$309.9M+14.9%
Gross profit$140.4M+26.5%
Operating income$16.9M+245%
Net income$11.4M+262%
EPS (diluted)$0.25+267%

Balance sheet

See full
Cash & equivalents$291.0M-29.8%
Total debt$34.3M-23.1%
Total equity$1.3B0.0%
Total assets$2.0B-6.8%

Cash flow

See full
Operating cash flow$54.5M+110%
CapEx$12.4M+11.3%
Free cash flow$42.1M+185%

Valuation

See full
Market cap$1.8B-7.2%
Enterprise value$1.54B-0.4%
P/E116.4×—
P/S1.5×-0.2×

Profitability

See full
Gross margin43.5%+0.4pp
Operating margin2.7%+1.8pp
Net margin1.7%+1.1pp
FCF margin9.3%-1.7pp

Returns & leverage

See full
Return on equity1.6%+1.1pp
Debt / equity0×0.0×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Omnicell in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omnicell's convertible debt (non-current)?
Omnicell (OMCL) reported convertible debt (non-current) of $167.9M in Q1 2026.
How has Omnicell's convertible debt (non-current) changed year-over-year?
Omnicell's convertible debt (non-current) increased by 0.7% year-over-year, from $166.7M to $167.9M.
What is the long-term trend for Omnicell's convertible debt (non-current)?
Over 5 years (2020 to 2025), Omnicell's convertible debt (non-current) has grown at a -18.5% compound annual growth rate (CAGR), from $467.2M to $167.6M.
What does convertible debt (non-current) mean?
This represents the principal amount of convertible debt obligations that are due beyond the one-year horizon. It reflects the company's long-term capital structure and the extent to which it relies on hybrid financing instruments that offer lower interest costs in exchange for potential equity conversion. Investors use this to assess long-term debt obligations and the potential for future share dilution upon maturity or conversion.